UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

The approach to the patient who refuses blood transfusion

Author
Kendall P Crookston, MD, PhD
Section Editor
Arthur J Silvergleid, MD
Deputy Editor
Jennifer S Tirnauer, MD

INTRODUCTION

Disagreements arising between patients and their clinicians on the choice of therapy remain a challenge in the practice of modern medicine. Such conflicts can strain the critical clinician/patient relationship [1,2]. Few disagreements have drawn as much attention in the medical, legal, and public spheres as the refusal of blood transfusion [3,4].

Dealing with such patients and their families takes additional time and energy, which may not be available in emergency situations and may not be reimbursed. Nevertheless, clinicians are obliged to provide the best management possible, factoring in the time required to assess the specific preferences of patients and their families. A thorough understanding of these issues, combined with a precise determination of the patient’s wishes, will enable a clinician to outline the most appropriate treatment plan or to refer the patient to an appropriate colleague when clinically possible.

This topic review will present an overview of this subject, often called "bloodless medicine," which is now evolving into the field of "patient blood management" [5]. Given the paucity of specific clinical guidelines, the approach discussed here reflects prevailing concepts generalizable to all medical specialties.  

General discussions of the use of blood for transfusion (ie, red blood cells [RBCs], white blood cells [WBCs], platelets, plasma) as well as the risks of transfusion are presented in separate UpToDate reviews:

Transfusion:

                               

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Thu Aug 11 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Henderson R, Jabbour N, Zeger G. Legal and administrative issues relate to transfusion-free medicine and surgery. In: Transfusion-free medicine and surgery, Jabbor N (Ed), Blackwell, Malden, MA 2005. p.1.
  2. Nash MJ, Cohen H. Management of Jehovah's Witness patients with haematological problems. Blood Rev 2004; 18:211.
  3. Gyamfi C, Gyamfi MM, Berkowitz RL. Ethical and medicolegal considerations in the obstetric care of a Jehovah's Witness. Obstet Gynecol 2003; 102:173.
  4. Rogers DM, Crookston KP. The approach to the patient who refuses blood transfusion. Transfusion 2006; 46:1471.
  5. Shander A, Javidroozi M, Perelman S, et al. From bloodless surgery to patient blood management. Mt Sinai J Med 2012; 79:56.
  6. Carson JL, Noveck H, Berlin JA, Gould SA. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion 2002; 42:812.
  7. Tobian AA, Ness PM, Noveck H, Carson JL. Time course and etiology of death in patients with severe anemia. Transfusion 2009; 49:1395.
  8. Shander A, Javidroozi M, Naqvi S, et al. An update on mortality and morbidity in patients with very low postoperative hemoglobin levels who decline blood transfusion (CME). Transfusion 2014; 54:2688.
  9. Jo KI, Shin JW, Choi TY, et al. Eight-year experience of bloodless surgery at a tertiary care hospital in Korea. Transfusion 2013; 53:948.
  10. Goodnough LT. Risks of blood transfusion. Anesthesiol Clin North America 2005; 23:241.
  11. http://www.fda.gov/biologicsbloodvaccines/safetyavailability/reportaproblem/transfusiondonationfatalities/ucm254802.htm (Accessed on May 13, 2013).
  12. Refaai MA, Blumberg N. Transfusion immunomodulation from a clinical perspective: an update. Expert Rev Hematol 2013; 6:653.
  13. West JM. Ethical issues in the care of Jehovah's Witnesses. Curr Opin Anaesthesiol 2014; 27:170.
  14. Bodnaruk ZM, Wong CJ, Thomas MJ. Meeting the clinical challenge of care for Jehovah's Witnesses. Transfus Med Rev 2004; 18:105.
  15. Bennett DR, Shulman IA. Practical issues when confronting the patient who refuses blood transfusion therapy. Am J Clin Pathol 1997; 107:S23.
  16. Berend K, Levi M. Management of adult Jehovah's Witness patients with acute bleeding. Am J Med 2009; 122:1071.
  17. http://wol.jw.org/en/wol/d/r1/lp-e/2004444 (Accessed on October 07, 2013).
  18. http://wol.jw.org/en/wol/d/r1/lp-e/2000767#h=13:0-16:183 (Accessed on October 07, 2013).
  19. Finucane ML, Slovic P, Mertz CK. Public perception of the risk of blood transfusion. Transfusion 2000; 40:1017.
  20. Shaner DM, Prema J. Conversation and the Jehovah's Witness dying from blood loss. Narrat Inq Bioeth 2014; 4:253.
  21. Petrini C. Ethical and legal aspects of refusal of blood transfusions by Jehovah's Witnesses, with particular reference to Italy. Blood Transfus 2014; 12 Suppl 1:s395.
  22. Muramoto O. Bioethical aspects of the recent changes in the policy of refusal of blood by Jehovah's witnesses. BMJ 2001; 322:37.
  23. Malyon D. Transfusion-free treatment of Jehovah's Witnesses: respecting the autonomous patient's rights. J Med Ethics 1998; 24:302.
  24. Van Wolfswinkel ME, Zwart JJ, Schutte JM, et al. Maternal mortality and serious maternal morbidity in Jehovah's witnesses in The Netherlands. BJOG 2009; 116:1103.
  25. Doyle DJ. Blood transfusions and the Jehovah's Witness patient. Am J Ther 2002; 9:417.
  26. Gyamfi C, Berkowitz RL. Responses by pregnant Jehovah's Witnesses on health care proxies. Obstet Gynecol 2004; 104:541.
  27. Lockhart E, Stover JC, Broomer BW, et al. Acceptance of Cryoprecipitate and Cryosupernatant by Adult Jehovah’s Witness Patients after Informed Consent [abstract]. Transfusion 2012; 52:113A.
  28. Campbell BH. A piece of my mind. Listening to leviticus. JAMA 2008; 299:879.
  29. Meier DE, Back AL, Morrison RS. The inner life of physicians and care of the seriously ill. JAMA 2001; 286:3007.
  30. Chigbu B, Onwere S, Kamanu C, et al. Lessons learned from the outcome of bloodless emergency laparotomies on Jehovah's Witness women presenting in the extremis with ruptured uterus. Arch Gynecol Obstet 2009; 279:469.
  31. Belfort M, Kofford S, Varner M. Massive obstetric hemorrhage in a Jehovah's Witness: intraoperative strategies and high-dose erythropoietin use. Am J Perinatol 2011; 28:207.
  32. Arab TS, Al-Wazzan AB, Maslow K. Postpartum hemorrhage in a Jehovah's Witness patient controlled with Tisseel, tranexamic acid, and recombinant factor VIIa. J Obstet Gynaecol Can 2010; 32:984.
  33. Mackenzie CF, Morrison C, Jaberi M, et al. Management of hemorrhagic shock when blood is not an option. J Clin Anesth 2008; 20:538.
  34. Siddiqui FM, Slater RM, Razzaq I, et al. Tourniquet use during total knee replacement in a Jehovah's Witness with sickle cell trait: a case report. Eur J Anaesthesiol 2010; 27:581.
  35. Emmert MY, Salzberg SP, Theusinger OM, et al. How good patient blood management leads to excellent outcomes in Jehovah's witness patients undergoing cardiac surgery. Interact Cardiovasc Thorac Surg 2011; 12:183.
  36. Hughes DB, Ullery BW, Barie PS. The contemporary approach to the care of Jehovah's witnesses. J Trauma 2008; 65:237.
  37. Dyer C. Doctors need not give blood transfusion to mentally ill Jehovah's Witness, judge rules. BMJ 2014; 348:g2950.
  38. Dyer C. Patient dies after judge gives UK hospital trust permission to withhold blood products. BMJ 2014; 348:g1844.
  39. Grinberg M, Zlotnik GC. Attitudes in the doctor-patient relationship Jehovah's Witnesses. Arq Bras Cardiol 2011; 97:e56.
  40. Remmers PA, Speer AJ. Clinical strategies in the medical care of Jehovah's Witnesses. Am J Med 2006; 119:1013.
  41. Hua M, Munson R, Lucas A, et al. Medical treatment of Jehovah's witnesses. Surgery 2008; 143:463.
  42. Jones JW, McCullough LB. Operating one-handed: emergency treatment of Jehovah's Witnesses. J Vasc Surg 2013; 57:573.
  43. COMMITTEE ON BIOETHICS. Informed Consent in Decision-Making in Pediatric Practice. Pediatrics 2016; 138.
  44. Ohto H, Yonemura Y, Takeda J, et al. Guidelines for managing conscientious objection to blood transfusion. Transfus Med Rev 2009; 23:221.
  45. Effa-Heap G. Blood transfusion: implications of treating a Jehovah's Witness patient. Br J Nurs 2009; 18:174.
  46. Kitney L, Kanani R, De Souza C. A Jehovah's Witness adolescent with pancytopenia. CMAJ 2012; 184:1055.
  47. Barth WH Jr, Kwolek CJ, Abrams JL, et al. Case records of the Massachusetts General Hospital. Case 23-2011. A 40-year-old pregnant woman with placenta accreta who declined blood products. N Engl J Med 2011; 365:359.
  48. www.watchtower.org (Accessed on August 03, 2009).
  49. Bock GL. Jehovah's Witnesses and autonomy: honouring the refusal of blood transfusions. J Med Ethics 2012; 38:652.
  50. Naunheim KS, Bridges CR, Sade RM. Should a Jehovah's Witness patient who faces imminent exsanguination be transfused? Ann Thorac Surg 2011; 92:1559.
  51. Goodnough LT, Shander A, Spence R. Bloodless medicine: clinical care without allogeneic blood transfusion. Transfusion 2003; 43:668.
  52. Shander A, Goodnough LT. Objectives and limitations of bloodless medical care. Curr Opin Hematol 2006; 13:462.
  53. Frank SM, Wick EC, Dezern AE, et al. Risk-adjusted clinical outcomes in patients enrolled in a bloodless program. Transfusion 2014; 54:2668.
  54. Hashem B, Dillard TA. A 44-year-old Jehovah's Witness with life-threatening anemia from uterine bleeding. Chest 2004; 125:1151.
  55. Schwenk MH, Blaustein DA. Rapid, high-dose intravenous iron sucrose therapy in 2 Jehovah's Witness patients with severe anemia, iron deficiency and chronic kidney disease. Clin Nephrol 2004; 62:116.
  56. Price S, Pepper JR, Jaggar SI. Recombinant human erythropoietin use in a critically ill Jehovah's witness after cardiac surgery. Anesth Analg 2005; 101:325.
  57. Jabbour N, Gagandeep S, Mateo R, et al. Live donor liver transplantation without blood products: strategies developed for Jehovah's Witnesses offer broad application. Ann Surg 2004; 240:350.
  58. Kickler TS. Why "bloodless medicine" and how should we do it? Transfusion 2003; 43:550.
  59. Savarese D, Waitkus H, Stewart FM, Callery M. Bloodless medicine and surgery. J Intensive Care Med 1999; 14:20.
  60. Resar LM, Frank SM. Bloodless medicine: what to do when you can't transfuse. Hematology Am Soc Hematol Educ Program 2014; 2014:553.
  61. Bhaskar B, Jack RK, Mullany D, Fraser J. Comparison of outcome in Jehovah's Witness patients in cardiac surgery: an Australian experience. Heart Lung Circ 2010; 19:655.
  62. Moraca RJ, Wanamaker KM, Bailey SH, et al. Strategies and outcomes of cardiac surgery in Jehovah's Witnesses. J Card Surg 2011; 26:135.
  63. Pattakos G, Koch CG, Brizzio ME, et al. Outcome of patients who refuse transfusion after cardiac surgery: a natural experiment with severe blood conservation. Arch Intern Med 2012; 172:1154.
  64. Jabbour N, Gagandeep S, Mateo R, et al. Transfusion free surgery: single institution experience of 27 consecutive liver transplants in Jehovah's Witnesses. J Am Coll Surg 2005; 201:412.
  65. Boggi U, Vistoli F, Del Chiaro M, et al. Kidney and pancreas transplants in Jehovah's witnesses: ethical and practical implications. Transplant Proc 2004; 36:601.
  66. Darwish A. Liver transplant in Jehovah's Witnesses patients. Curr Opin Organ Transplant 2011; 16:326.
  67. Ballen KK, Becker PS, Yeap BY, et al. Autologous stem-cell transplantation can be performed safely without the use of blood-product support. J Clin Oncol 2004; 22:4087.
  68. Mazza P, Prudenzano A, Amurri B, et al. Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experience. Bone Marrow Transplant 2003; 32:433.
  69. Sloan JM, Ballen K. SCT in Jehovah's Witnesses: the bloodless transplant. Bone Marrow Transplant 2008; 41:837.
  70. Brown NM, Kim SY, Ford PA. Autologous stem cell transplants in Jehovah's Witnesses. Bone Marrow Transplant 2009; 44:391.
  71. Laszlo D, Agazzi A, Goldhirsch A, et al. Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. Eur J Haematol 2004; 72:264.
  72. Bareford D, Odeh B, Narayanan S, Wiltshire S. Remission induction in a Jehovah's witness patient with acute myeloid leukaemia using gemtuzumab ozogamicin. Transfus Med 2005; 15:445.
  73. Brown NM, Keck G, Ford PA. Acute myeloid leukemia in Jehovah Witnesses. Leuk Lymphoma 2008; 49:817.
  74. Dhanoa A, Singh VA, Shanmugam R, Rajendram R. Major surgery in an osteosarcoma patient refusing blood transfusion: case report. World J Surg Oncol 2010; 8:96.
  75. Greensmith JE. Hyperbaric oxygen reverses organ dysfunction in severe anemia. Anesthesiology 2000; 93:1149.
  76. Oh SY, Kim SH, Kwon HC, et al. Bloodless cancer treatment results of patients who do not want blood transfusion: single center experience of 77 cases. Support Care Cancer 2010; 18:1341.
  77. Weinstein A, Chandra P, Schiavello H, Fleischer A. Conservative management of placenta previa percreta in a Jehovah's Witness. Obstet Gynecol 2005; 105:1247.
  78. Nagy CJ, Wheeler AS, Archer TL. Acute normovolemic hemodilution, intraoperative cell salvage and PulseCO hemodynamic monitoring in a Jehovah's Witness with placenta percreta. Int J Obstet Anesth 2008; 17:159.
  79. Holt RL, Martin TD, Hess PJ, et al. Jehovah's Witnesses requiring complex urgent cardiothoracic surgery. Ann Thorac Surg 2004; 78:695.
  80. McCartney S, Guinn N, Roberson R, et al. Jehovah's Witnesses and cardiac surgery: a single institution's experience. Transfusion 2014; 54:2745.
  81. Binder RK, Barbanti M, Ye J, et al. Blood loss and transfusion rates associated with transcatheter aortic valve replacement: recommendations for patients who refuse blood transfusion. Catheter Cardiovasc Interv 2014; 83:E221.
  82. Haan J, Scalea T. A Jehovah's Witness with complex abdominal trauma and coagulopathy: use of factor VII and a review of the literature. Am Surg 2005; 71:414.
  83. Creelan B, Thomas K, Massis K, Davis RM. Splenic arterial embolization for idiopathic warm auto-immune haemolytic anaemia. Br J Haematol 2013; 161:2.
  84. Marinaro J, Smith J, Tawil I, et al. HBOC-201 use in traumatic brain injury: case report and review of literature. Transfusion 2009; 49:2054.
  85. Ballen J, Raabe M, Muirhead B. Aortic dissection and hypothermic arrest in a Jehovah's Witness patient: a case for recombinant factor VIIa? Can J Anaesth 2006; 53:353.
  86. Namura O, Kanazawa H, Yoshiya K, et al. Successful surgical treatment of a ruptured abdominal aortic aneurysm without homologous blood transfusion in a Jehovah's Witness: report of a case. Surg Today 2001; 31:912.
  87. Martin MG, Whitlatch NL, Shah B, Arepally GM. Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole in a Jehovah's Witness. Am J Hematol 2007; 82:679.
  88. Dabak V, Kuriakose P, Raman S. Successful management of a Jehovah's Witness with thrombotic thrombocytopenic purpura unwilling to be treated with therapeutic plasma exchange. J Clin Apher 2007; 22:330.
  89. Sharma P, Barajas FJ, Krishnamoorthy P, et al. Transfusion-free management of gastrointestinal bleeding: the experience of a bloodless institute. J Clin Gastroenterol 2015; 49:206.
  90. Fowler RA, Rizoli SB, Levin PD, Smith T. Blood conservation for critically ill patients. Crit Care Clin 2004; 20:313.
  91. Helm RE, Rosengart TK, Gomez M, et al. Comprehensive multimodality blood conservation: 100 consecutive CABG operations without transfusion. Ann Thorac Surg 1998; 65:125.
  92. Cid J, Lozano M. Tranexamic acid reduces allogeneic red cell transfusions in patients undergoing total knee arthroplasty: results of a meta-analysis of randomized controlled trials. Transfusion 2005; 45:1302.
  93. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356:2301.
  94. Alvarez JC, Santiveri FX, Ramos I, et al. Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied. Transfusion 2008; 48:519.
  95. Waddington DP, McAuley FT, Hanley JP, Summerfield GP. The use of recombinant factor viia in a jehovah's witness with auto-immune thrombocytopenia and post-splenectomy haemorrhage. Br J Haematol 2002; 119:286.
  96. Veneri D, Franchini M. Successful treatment of intestinal hemorrhage in a Jehovah's Witness patient. Am J Hematol 2005; 79:344.
  97. Tanaka KA, Waly AA, Cooper WA, Levy JH. Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). Anesthesiology 2003; 98:1513.
  98. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363:1791.
  99. Lin Y, Stanworth S, Birchall J, et al. Use of recombinant factor VIIa for the prevention and treatment of bleeding in patients without hemophilia: a systematic review and meta-analysis. CMAJ 2011; 183:E9.
  100. Robblee JA, Wilkes PR, Dickie SJ, et al. Bleeding in a Jehovah's Witness patient undergoing a redo aortic valve replacement controlled with cryoprecipitate and a prothrombin complex concentrate. Can J Anaesth 2012; 59:299.
  101. Levy JH, Goodnough LT. How I use fibrinogen replacement therapy in acquired bleeding. Blood 2015; 125:1387.
  102. Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Brown JR, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011; 91:944.
  103. Crosby E. Perioperative use of erythropoietin. Am J Ther 2002; 9:371.
  104. WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm260670.htm (Accessed on May 13, 2013).
  105. http://www.procrit.com/professionals/elective_surgery (Accessed on May 13, 2013).
  106. Ball AM, Winstead PS. Recombinant human erythropoietin therapy in critically ill Jehovah's Witnesses. Pharmacotherapy 2008; 28:1383.
  107. Brecher ME, Goodnough LT. The rise and fall of preoperative autologous blood donation. Transfusion 2001; 41:1459.
  108. Shander A, Rijhwani TS. Acute normovolemic hemodilution. Transfusion 2004; 44:26S.
  109. Goodnough LT. Autologous blood donation. Anesthesiol Clin North America 2005; 23:263.
  110. Simoni J. Artificial oxygen carriers: renewed commercial interest and scientific/technological advances. Artif Organs 2012; 36:123.
  111. Elmer J, Alam HB, Wilcox SR. Hemoglobin-based oxygen carriers for hemorrhagic shock. Resuscitation 2012; 83:285.
  112. Watch Tower Bible and Tract Society. Questions from Readers: Do Jehovah's Witnesses accept any medical products derived from blood? Watchtower 2000; (June 15):29.
  113. Weiskopf RB. Hemoglobin-based oxygen carriers: compassionate use and compassionate clinical trials. Anesth Analg 2010; 110:659.
  114. https://clinicaltrials.gov/ct2/show/NCT01881503 (Accessed on December 01, 2015).
  115. Van Meter KW. A systematic review of the application of hyperbaric oxygen in the treatment of severe anemia: an evidence-based approach. Undersea Hyperb Med 2005; 32:61.
  116. Available at: <www.watchtower.org>. Accessed August 3, 2009.
  117. Marsh JC, Bevan DH. Haematological care of the Jehovah's Witness patient. Br J Haematol 2002; 119:25.